Related references
Note: Only part of the references are listed.The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease
Tomer Greener et al.
JOURNAL OF CROHNS & COLITIS (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG)
Gustav L. Jakobsson et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)
Can We Predict the Efficacy of Anti-TNF-alpha Agents?
Loris Riccardo Lopetuso et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study
C. Martineau et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF- naive Crohn's disease
N. Narula et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
J. Cosnes et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Golimumab Therapy in Six Patients With Severe Pediatric Onset Crohn Disease
Laura Merras-Salmio et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
P. Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys
Jason P. Gordon et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience
Ofer Ben-Bassat et al.
GASTROENTEROLOGY (2015)
Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study
K. Busch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
European consensus on the histopathology of inflammatory bowel disease
F. Magro et al.
JOURNAL OF CROHNS & COLITIS (2013)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Share Paper
